Top Tumor Suppressor Genes Explained

The Two-Hit Hypothesis and Biallelic Tumour Suppressor Inactivation

Knudson's two-hit model proposes that cancer requires inactivation of both alleles of a tumor suppressor gene. In hereditary retinoblastoma, patients inherit one mutant RB1 allele (the first hit) and require only a single somatic mutation in the remaining allele (the second hit) to develop tumours — explaining why hereditary cancers appear at young ages and in multiple sites.

In sporadic cancers, both hits must occur independently in the same somatic cell, explaining later onset and unilateral presentation. The same principle applies to TP53 in Li-Fraumeni syndrome, BRCA1 in hereditary breast cancer, and APC in familial adenomatous polyposis. The downstream signalling consequences of tumour suppressor loss define the therapeutic vulnerabilities — BRCA1 loss creates PARP inhibitor synthetic lethality; PTEN loss creates PI3K/AKT/mTOR pathway dependency.

TP53: Guardian of the Genome

TP53 is the most frequently mutated gene in human cancer, altered in over 50% of all tumour types. The p53 protein integrates stress signals — DNA double-strand breaks (via ATM), oncogene activation (via ARF/CDKN2A), and hypoxia (via HIF1A) — and decides whether the affected cell should arrest, repair, senesce, or undergo apoptosis.

After DNA damage, p53 is stabilised by inhibition of its principal negative regulator MDM2, then transcriptionally activates CDKN1A (encoding p21). p21 binds and inactivates CDK2 and CDK4 complexes, imposing G1 cell cycle arrest. If damage cannot be repaired, p53 activates pro-apoptotic targets including BAX and PUMA, initiating mitochondrial outer membrane permeabilisation and the intrinsic apoptosis pathway.

Germline TP53 mutations cause Li-Fraumeni syndrome, conferring nearly 100% lifetime cancer risk across multiple tissue types. The spectrum of TP53 mutations in sporadic cancer is remarkably consistent: ~75% are missense mutations that produce a stable but non-functional protein, often with dominant-negative effects on the remaining wild-type allele.

BRCA1 and Homologous Recombination

BRCA1 is a multifunctional protein, but its critical tumour suppressor role lies in homologous recombination (HR) — the high-fidelity repair of DNA double-strand breaks. BRCA1 is recruited to break sites within seconds, where it nucleates a multi-protein complex including PALB2, BRCA2, and RAD51 that uses the intact sister chromatid as a template for faithful sequence reconstruction.

Loss of BRCA1 function forces cells to rely on error-prone repair pathways including non-homologous end joining (NHEJ) and microhomology-mediated end joining (MMEJ), which introduce deletions and translocations that accumulate over time. This 'BRCAness' phenotype creates a targetable vulnerability: PARP inhibitors (olaparib, niraparib) exploit synthetic lethality by blocking the single-strand break repair pathway that BRCA1-deficient cells depend on.

Carriers of germline BRCA1 mutations face approximately 50–70% lifetime breast cancer risk and 40–45% ovarian cancer risk. Risk-reducing salpingo-oophorectomy by age 35–40 in BRCA1 carriers significantly reduces ovarian cancer mortality.

PTEN and PI3K Pathway Control

PTEN is a dual-specificity phosphatase whose lipid phosphatase activity dephosphorylates PIP3 to PIP2, directly opposing the activity of PI3K. This positions PTEN as the primary negative regulator of the PI3K/AKT/mTOR axis — the most commonly activated oncogenic pathway in human cancer, altered in over 70% of tumours.

PTEN loss results in constitutive AKT activation and unrestrained mTORC1 signalling, driving protein synthesis, metabolic reprogramming, and cell survival. Germline PTEN mutations cause Cowden syndrome, while somatic loss occurs in ~30% of glioblastomas, prostate cancers, and endometrial cancers. The PI3Kα inhibitor alpelisib is approved for PIK3CA-mutant breast cancer, and AKT inhibitors are active in PTEN-deficient tumours.

RB1 and the Cell Cycle Restriction Point

The retinoblastoma protein (pRb, encoded by RB1) is the molecular enforcer of the G1 restriction point. In its active hypophosphorylated state, pRb binds E2F transcription factors and recruits histone deacetylases to silence S-phase genes. CDK4/CDK6-cyclin D complexes phosphorylate pRb during mid-G1, releasing E2F and irreversibly committing the cell to division.

Biallelic RB1 inactivation causes retinoblastoma, the prototype for Knudson's two-hit model. Somatic RB1 loss is near-universal in small cell lung cancer (~90%), common in bladder cancer and osteosarcoma. Almost every human cancer disrupts the RB pathway at some level — through RB1 mutation, CDKN2A deletion, CDK4 amplification, or cyclin D overexpression — underscoring the restriction point as the most universally targeted cell cycle control in oncogenesis.

ATM and the DNA Damage Response

ATM is a master kinase that translates the physical presence of a DNA double-strand break (detected by the MRN complex) into a coordinated cellular response. Within minutes of damage, ATM phosphorylates H2AX (forming γH2AX foci visible by microscopy), CHK2, BRCA1, and p53, simultaneously activating repair and imposing checkpoints at G1/S, intra-S, and G2/M.

Germline ATM mutations cause ataxia-telangiectasia, characterised by cerebellar ataxia, telangiectasias, immunodeficiency, extreme radiosensitivity, and lymphoma predisposition. Heterozygous ATM carriers have moderately elevated breast and pancreatic cancer risk and respond well to platinum chemotherapy and PARP inhibitors due to HR deficiency.

CDKN2A: Two Suppressors, One Locus

CDKN2A is among the most frequently deleted loci in human cancer for a compelling reason: it encodes two completely separate tumor suppressor proteins from overlapping reading frames. p16INK4a inhibits CDK4/CDK6 to prevent pRb phosphorylation, directly protecting the G1 checkpoint. p14ARF sequesters MDM2 in the nucleolus, amplifying p53 stability and activity.

A single CDKN2A deletion therefore simultaneously disables both the RB and p53 pathways — two of the three most critical tumour suppressor circuits. Homozygous deletion occurs in ~50% of melanomas, ~30% of glioblastomas, and virtually all pancreatic cancers. The p16INK4a promoter is also one of the most commonly methylation-silenced loci in cancer and precancerous fields.